Gefitinib, the first EGFR tyrosine kinase inhibitor put into clinical trial, was put into market in Japan in 2002.

• 吉非替尼是EGFR酪氨酸激酶抑制剂中最早进入临床试验的口服药物，2002年首次于日本上市。